A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 22 Jan 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 11 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Oct 2018 Planned initiation date changed from 21 Sep 2018 to 21 Dec 2018.